Special Issue "Proteomic Studies for the Identification and Characterization of Marine Bioactive Molecules"

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Biotechnology Related to Drug Discovery or Production".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 1253

Special Issue Editor

1. School of Health and Human Sciences, Southern Cross University, Gold Coast, QLD 4225, Australia
2. Marine Ecology Research Centre, Southern Cross University, Lismore, Military Rd., East Lismore, NSW 2480, Australia
Interests: marine biology; sequencing; molecular biology; biomedical products; gene expression; genomics; molecular genetics; epigenetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The marine environment provides a rich source of bioactive compounds which could be efficiently applied in various industries, benefiting the shift towards environmentally sustainable green sectors, environmental protection, and the balanced use of natural resources. Proteomic studies assess all proteins produced in organisms, differential gene expression, and its impact on proteomics profiles, as well as proteins’ activity, stability, degradation, modification, interactions, and their effect on metabolic pathways. Wide-ranging aspects of proteomics research are emerging, including modern technologies implementing artificial intelligence (AI)-based methods. The extension of knowledge regarding proteomics facilitates a better understanding of the bioactive capacities of bioproducts found in aquatic species and is especially important in the field of medical research, which urgently requires new and improved drug therapies.

We would like to invite scientists to submit their high-quality studies, including novel research and review articles addressing proteomics research, to this Special Issue of Marine Drugs in relation to the following topics:

  • Protein expression profiling and the influence of differential gene expression;
  • Proteome mining for the identification of biological target molecules;
  • Post-translational modification of proteins and impact on the function;
  • Functional proteomics, including protein production, degradation, and/or stability;
  • Structural proteomics and protein–protein interactions.

Dr. Nedeljka Rosic
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • proteomics
  • bioproducts
  • anti-bacterial
  • anti-tumour
  • anti-viral
  • anti-aging
  • anti-inflammatory
  • anti-fungal

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Proteomic Identification of Plasma Components in Tachypleus tridentatus and Their Effects on the Longitudinal Bone Growth Rate in Rats
Mar. Drugs 2023, 21(2), 111; https://doi.org/10.3390/md21020111 - 03 Feb 2023
Viewed by 892
Tachypleus tridentatus (T. tridentatus) is a marine animal and traditional Chinese medicine. T. tridentatus plasma is a valuable resource for important medical and health-based functions. In this experiment, in order to evaluate the effect and mechanism of T. tridentatus plasma with [...] Read more.
Tachypleus tridentatus (T. tridentatus) is a marine animal and traditional Chinese medicine. T. tridentatus plasma is a valuable resource for important medical and health-based functions. In this experiment, in order to evaluate the effect and mechanism of T. tridentatus plasma with respect to the promotion of bone tissue growth in rats, the processes of ultrafiltration and mass spectrometry were first used to separate and identify the components of T. tridentatus plasma. Then, a comparison of the effects of the T. tridentatus plasma samples, which each possessed different molecular weights, regarding the growth of the long bones of rats was conducted. Finally, transcriptomics, proteomics, and bioinformatics were all used to analyze the biological functions and related signaling pathways of the T. tridentatus plasma in order to promote rat bone growth. The results showed that the contents of amino acid residues in peptides are related to the growth promotion that was contained in the 10–30 kDa plasma group. Moreover, the T. tridentatus plasma samples were found to be higher in this respect than those in the whole plasma group. In addition, the 10–30 kDa plasma group could significantly promote bone growth activity in rats. The proteomic analysis showed that the proteins that were differentially expressed in the 10–30 kDa plasma group were mainly enriched in the PI3K-AKT signal pathway. Our study suggested that the T. tridentatus plasma possesses promising potential for the purposes of clinical use, whereby it can serve the role of a growth-promoting agent. Full article
Show Figures

Figure 1

Back to TopTop